InsidersTradesSigma
Follow the ブライトパス・バイオ share price and the full directors' dealings record of the company, a listed equity based in Japan. Shares trade on JP JP, under the supervision of EDINET (Japan FSA). Market capitalisation: €6.5bn. The latest transaction was reported on 19 February 2026 (Holding update). Among the most active insiders: Phillip Securities Japan,Ltd.. All data is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
8 of 8 declarations
BrightPath Bio is a company focused on developing innovative therapies in biotechnology. It is listed on the XTKS market.